• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Blog » An Off-Label Guide to Gabapentin | Anxiety, Sleep, Addiction, Pain, & More

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

An Off-Label Guide to Gabapentin | Anxiety, Sleep, Addiction, Pain, & More

August 8, 2024
Greg Malzberg, MD, Chris Aiken, MD, and Rajesh R. Tampi, MD, MS, DFAPA.
Screenshot 2024-08-13 at 4.19.27 PM.png


In today’s video, we explore the off-label uses of Gabapentin, also known as Neurontin. While Gabapentin is FDA-approved for partial seizures and postherpetic neuralgia, its off-label uses are more extensive, especially in psychiatry. Gabapentin for anxiety disorders is notable, with doses between 900 and 3,600 milligrams per day showing effectiveness in reducing symptoms. Though clinical trials are small, Gabapentin and alcohol interactions suggest benefits in patients with alcohol use disorders.

Additionally, Gabapentin for pain is effective for neuropathic pain conditions like postherpetic neuralgia but not recommended for common pain conditions. For sleep issues, Gabapentin for sleep can enhance sleep quality, though it may not aid in falling asleep faster. It’s used for insomnia, improving sleep depth and reducing nocturnal awakenings. Gabapentin’s role in managing alcohol and cannabis use disorders is significant. It reduces heavy drinking days and improves sleep quality during alcohol recovery. However, caution is needed during alcohol withdrawal due to potential seizures. Gabapentin for cannabis use disorder shows promise, although it’s not effective for all addictions. Gabapentin also treats restless leg syndrome (RLS), with doses up to 2,400 milligrams proving effective, despite FDA approval being limited to Gabapentin enacarbil. It helps manage akathisia and hot flashes as well.

Side effects include sedation, dizziness, and fatigue. Gabapentin’s nonlinear pharmacokinetics mean absorption plateaus above 900 milligrams, and dose adjustments are necessary for renal impairment. In summary, Gabapentin is useful for managing anxiety, insomnia, addiction, and certain types of pain, though evidence varies. For a detailed fact sheet on Gabapentin, visit thecarlatreport.com and consider subscribing to the Carlat Psychiatry Report for updates and expert insights.

Related:

  • Prescription Drug Misuse
  • Substance Use Disorders in Older Adults: A Growing Concern
  • Gabapentin: A Double-Edged Sword
  • Management of Chronic Pain
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.